BILLION NOK COMBINED VALUE
OF PORTFOLIO COMPANIES
NEW LICENSE AGREEMENTS
NEW PATENT APPLICATIONS
NEW CLINICAL STUDIES
ONGOING CLINICAL STUDIES
NEW COMPANIES ESTABLISHED
MILLION NOK TO
MILLION NOK IN
PRIVATE CAPITAL RAISED
A word from the CEO
The year 2020 was the year of COVID-19. It was also Inven2’s tenth anniversary. However, it was also a year in which much value was created from the research carried out at the University of Oslo, Oslo University Hospital and the other health trusts in the South-Eastern Norway Regional Health Authority.Read more
– how do you take your research to market?
Inven2’s main area of focus is taking research results and turning them into a product or service in a market. This is done through a value chain that starts with idea hunting and marketing of Inven2’s services aimed at researchers at the University of Oslo and Oslo University Hospital.Read more
CLINICAL TRIALS ARE THE KEY TO MEDICAL DEVELOPMENT
Clinical trials involve testing new drugs and medical equipment on human subjects. Clinical trials can be conducted on both healthy volunteers and patients.Read more
Inven2 10 years
Inven2 was celebrating its tenth anniversary in 2020. In the last 10 years, Inven2 has established 55 companies, and the value creation of our portfolio has increased from half a billion kroner in 2010 to 17 billion in August 2020. More importantly, these companies have created jobs and socially beneficial products that are able to compete on the global market.
Here you can read the interview with CEO Ole Kristian Hjelstuen and interviews with five successful researchers and clinicians who have all worked on groundbreaking innovations with significant benefits for society.
The board of directors
Inven2 is one of Norway’s largest technology transfer offices (TTO), and our mandate is to commercialise research on behalf of our owners: the University of Oslo, Oslo University Hospital and the South-Eastern Norway Regional Health Authority.
Our board has broad insight into different fields of research, commercialisation, innovation, start-ups and knowledge-intensive business services.
There were a number of replacements in the board in 2020, and four new board members joined:
Idar Kreutzer, CEO of Finance Norway, Alexander Woxen, partner at Norselab Ventures, Tom Pike, who sits on different boards and has various roles in the healthcare sector and Jan Frich, Deputy CEO of the South-Eastern Norway Regional Health Authority.
A new employee representative, Lise Rødsten, who is Technology Strategy & Collaboration Manager at Inven2, was also elected to the board in 2020.
Åse Aulie Michelet chairs the board.
Making a difference by transforming knowledge into products and services for the benefit of society.
Research and knowledge are the keys to addressing global challenges relating to health, climate and the environment. Highly capable researchers and clinicians from larger parts Norway report their ideas and discoveries to us. We develop and manage these ideas, and proceed with the ones that can be transformed into products that benefit society.
We have started businesses that develop better cancer therapies, combat antibiotic resistance and identify security breaches in complex IT systems. Two-thirds of our businesses and licences are in the field of life science, since the scientific community we represent is particularly strong in that field.
Another important area for us is to administer agreements on clinical trials on behalf of the hospitals in our region and in the northern part of Norway. We make active endeavours to get more international companies to carry out their clinical trials in Norway. That way, more innovative treatment can benefit more patients in Norway.
Inven2 is a limited company owned by the University of Oslo and Oslo University Hospital. Inven2 currently has 32 employees.
Inven2 has a portfolio comprising 53 companies. 7 new companies were established in 2020. Together, the companies are worth around NOK 30 billion. The value of the portfolio increased by a total of 138 per cent in 2020, due, among other things, to the increase in the value of the companies Vaccibody ASA (357 %) and Ultimovacs ASA (134 %).
The companies raised a total of NOK 864 million for development purposes in 2020. At the same time, NOK 178 million was returned to inventors and to research at the institutions.
Inven2 want to make a difference by transforming research and knowledge into products and services for the benefit of society. We have contributed to the launching of many products and services. Here is a selection.
Inven2 is part of a vital, ever-growing ecosystem in research and development. The area near Inven2’s premises in Oslo Science Park is home to a number of clusters and incubators, as well as the University of Oslo and Oslo University Hospital.Read more
*Retired. New VP Innovation, Halvard Grønlien will take up the position on 1 February 2021.